Casdin Partners Master Fund, L Acquires 1,200,000 Shares of Standard BioTools Inc. (NASDAQ:LAB) Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L purchased 1,200,000 shares of the stock in a transaction dated Wednesday, August 14th. The shares were purchased at an average price of $1.59 per share, with a total value of $1,908,000.00. Following the completion of the acquisition, the director now owns 51,775,821 shares of the company’s stock, valued at $82,323,555.39. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Monday, August 12th, Casdin Partners Master Fund, L purchased 500,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.64 per share, with a total value of $820,000.00.
• On Friday, August 9th, Casdin Partners Master Fund, L bought 525,408 shares of Standard BioTools stock. The stock was bought at an average price of $1.61 per share, with a total value of $845,906.88.
• On Wednesday, August 7th, Casdin Partners Master Fund, L bought 500,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.57 per share, with a total value of $785,000.00.
• On Friday, August 2nd, Casdin Partners Master Fund, L bought 1,000,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.63 per share, with a total value of $1,630,000.00.
• On Monday, August 5th, Casdin Partners Master Fund, L bought 200,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.58 per share, with a total value of $316,000.00.
• On Wednesday, May 22nd, Casdin Partners Master Fund, L purchased 150,000 shares of Standard BioTools stock. The shares were acquired at an average cost of $2.58 per share, for a total transaction of $387,000.00.
• On Monday, May 20th, Casdin Partners Master Fund, L purchased 100,000 shares of Standard BioTools stock. The shares were acquired at an average cost of $2.58 per share, for a total transaction of $258,000.00.

Standard BioTools Stock Down 1.7 %

Shares of NASDAQ LAB traded down $0.03 during trading on Friday, reaching $1.77. 1,725,677 shares of the stock were exchanged, compared to its average volume of 2,709,510. The business’s 50-day moving average price is $1.96 and its 200 day moving average price is $2.34. Standard BioTools Inc. has a twelve month low of $1.21 and a twelve month high of $3.16. The company has a market capitalization of $655.65 million, a price-to-earnings ratio of -1.74 and a beta of 1.67.

Analyst Ratings Changes

Separately, TD Cowen reduced their price target on shares of Standard BioTools from $3.50 to $2.75 and set a “buy” rating on the stock in a research report on Thursday, August 1st.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in LAB. Hollow Brook Wealth Management LLC lifted its position in shares of Standard BioTools by 5.0% during the fourth quarter. Hollow Brook Wealth Management LLC now owns 1,874,405 shares of the company’s stock worth $4,142,000 after purchasing an additional 88,648 shares in the last quarter. Jump Financial LLC lifted its position in shares of Standard BioTools by 117.2% during the fourth quarter. Jump Financial LLC now owns 70,480 shares of the company’s stock worth $156,000 after purchasing an additional 38,030 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Standard BioTools in the fourth quarter valued at $55,000. Parkman Healthcare Partners LLC raised its holdings in Standard BioTools by 20.7% in the fourth quarter. Parkman Healthcare Partners LLC now owns 603,620 shares of the company’s stock valued at $1,334,000 after acquiring an additional 103,620 shares in the last quarter. Finally, HBK Investments L P acquired a new stake in Standard BioTools in the fourth quarter valued at $333,000. 53.74% of the stock is owned by institutional investors and hedge funds.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.